On the other hand, although pembrolizumab failed to show superiority to paclitaxel in second-line gastric cancer treatment in KEYNOTE-061, post-hoc analysis revealed that the treatment effect was greater in patients with a PD-L1 CPS ≥10 than CPS ≥1 (4). The gene discussed is CD274; the disease is gastric cancer.